Mereo Biopharma Group Plc ADR (MREO)

$4.38 +0.03 (0.69%)
Market Cap 530.17M
Revenue (ttm) 10.00M
Net Income (ttm) -29.47M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 28,075
Avg Vol 812,584
Day's Range N/A - N/A
Shares Out 140.26M
Stochastic %K 30%
Beta 0.88
Analysts Strong Sell
Price Target $6.80

Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian ca...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 33 3023 7300
Address:
One Cavendish Place, 4th Floor, London, United Kingdom
Mike127
Mike127 Jan. 26 at 8:45 PM
$MREO lets go.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 24 at 2:50 AM
$MREO RSI: 51.15, MACD: -0.2880 Vol: 0.56, MA20: 0.69, MA50: 1.45 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
agentorangeboydondacon
agentorangeboydondacon Jan. 23 at 3:04 PM
$MREO gap up to .76 for slight pullback before another push
1 · Reply
Henry20feb_
Henry20feb_ Jan. 23 at 2:03 PM
$MREO Where Mereo stands now! In Between is Where Asymmetry is Born. The Opportunity Zone.
0 · Reply
Henry20feb_
Henry20feb_ Jan. 23 at 12:44 PM
$MREO
0 · Reply
Henry20feb_
Henry20feb_ Jan. 23 at 12:32 PM
$MREO
0 · Reply
saad545
saad545 Jan. 23 at 4:58 AM
$MREO don’t listen to these stupid son of bitch shorts, theg want to steal your money be selling your stock. The play here with patience. This will go to 3$
1 · Reply
realDrake
realDrake Jan. 22 at 9:34 PM
$MREO im not in this shitty stock anymore dumped a couple days ago. Lost 80$ sum. Rather trade something that actually has volume and lower share structures
2 · Reply
Brighams
Brighams Jan. 22 at 9:17 PM
$MREO Went up today
1 · Reply
slaykween
slaykween Jan. 22 at 7:39 PM
$MREO should i stay or should I go...... Hmmmmm
0 · Reply
Latest News on MREO
Mereo BioPharma Group plc (MREO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 6:55 PM EST - 12 days ago

Mereo BioPharma Group plc (MREO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

These biotech stocks are getting hammered by shocking brittle-bone treatment study results

Dec 29, 2025, 1:05 PM EST - 4 weeks ago

These biotech stocks are getting hammered by shocking brittle-bone treatment study results

RARE

Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta

Dec 29, 2025, 8:31 AM EST - 4 weeks ago

Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta

āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2

Aug 19, 2025, 8:30 AM EDT - 5 months ago

āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2

Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights

Aug 12, 2025, 7:35 AM EDT - 5 months ago

Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights

Mereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OI

Jul 10, 2025, 3:15 PM EDT - 7 months ago

Mereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OI

Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights

May 13, 2025, 7:30 AM EDT - 9 months ago

Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights

Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

Mar 26, 2025, 7:30 AM EDT - 10 months ago

Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference

Mar 5, 2025, 7:30 AM EST - 11 months ago

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference

Mereo BioPharma Provides Update on Lead Clinical Programs

Jan 12, 2025, 11:05 AM EST - 1 year ago

Mereo BioPharma Provides Update on Lead Clinical Programs

Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 7:30 AM EST - 1 year ago

Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Mereo BioPharma: Setrusumab Chugs Along With Possible Inflection Points

Nov 26, 2024, 1:36 PM EST - 1 year ago

Mereo BioPharma: Setrusumab Chugs Along With Possible Inflection Points

Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 1 year ago

Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 12, 2024, 7:30 AM EST - 1 year ago

Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference

Sep 12, 2024, 5:35 PM EDT - 1 year ago

Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference

Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market

Jun 14, 2024, 7:50 AM EDT - 1 year ago

Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market

Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

May 30, 2024, 7:30 AM EDT - 1 year ago

Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 15, 2024, 4:01 PM EDT - 1 year ago

Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 7:30 AM EDT - 1 year ago

Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 27, 2024, 4:01 PM EDT - 1 year ago

Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032

Mar 14, 2024, 5:34 PM EDT - 2 years ago

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032

KRRO KRYS TAK WVE

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference

Mar 5, 2024, 7:30 AM EST - 2 years ago

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference

Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments

Jan 8, 2024, 7:00 AM EST - 2 years ago

Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments

Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update

Oct 23, 2023, 4:01 PM EDT - 2 years ago

Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update

Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference

Sep 21, 2023, 7:00 AM EDT - 2 years ago

Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference

Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update

Sep 7, 2023, 7:30 AM EDT - 2 years ago

Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update

Mereo BioPharma to Present at the Jefferies Healthcare Conference

May 31, 2023, 7:00 AM EDT - 2 years ago

Mereo BioPharma to Present at the Jefferies Healthcare Conference

Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma's Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference

May 23, 2023, 1:43 PM EDT - 2 years ago

Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma's Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference

Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 8, 2023, 12:46 PM EDT - 2 years ago

Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market

May 5, 2023, 4:06 PM EDT - 2 years ago

Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market

Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights

Mar 28, 2023, 4:30 PM EDT - 3 years ago

Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights

Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease

Mar 21, 2023, 6:30 AM EDT - 3 years ago

Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease

Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference

Feb 8, 2023, 7:00 AM EST - 3 years ago

Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference

Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency

Nov 2, 2022, 4:01 PM EDT - 3 years ago

Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency

Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management

Oct 28, 2022, 7:00 AM EDT - 3 years ago

Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management

Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022

Oct 24, 2022, 4:30 PM EDT - 3 years ago

Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022

Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting

Oct 21, 2022, 7:00 AM EDT - 3 years ago

Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting

Rubric Capital Management Comments on Mereo BioPharma Updated Operating Plan

Oct 18, 2022, 11:58 AM EDT - 3 years ago

Rubric Capital Management Comments on Mereo BioPharma Updated Operating Plan

Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value

Oct 18, 2022, 7:00 AM EDT - 3 years ago

Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value

Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease

Oct 17, 2022, 7:00 AM EDT - 3 years ago

Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease

Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders

Oct 3, 2022, 5:00 PM EDT - 3 years ago

Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders

Rubric Capital Management Increases Slate of Proposed Mereo BioPharma Director Nominees to Five

Oct 3, 2022, 9:00 AM EDT - 3 years ago

Rubric Capital Management Increases Slate of Proposed Mereo BioPharma Director Nominees to Five

Mike127
Mike127 Jan. 26 at 8:45 PM
$MREO lets go.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 24 at 2:50 AM
$MREO RSI: 51.15, MACD: -0.2880 Vol: 0.56, MA20: 0.69, MA50: 1.45 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
agentorangeboydondacon
agentorangeboydondacon Jan. 23 at 3:04 PM
$MREO gap up to .76 for slight pullback before another push
1 · Reply
Henry20feb_
Henry20feb_ Jan. 23 at 2:03 PM
$MREO Where Mereo stands now! In Between is Where Asymmetry is Born. The Opportunity Zone.
0 · Reply
Henry20feb_
Henry20feb_ Jan. 23 at 12:44 PM
$MREO
0 · Reply
Henry20feb_
Henry20feb_ Jan. 23 at 12:32 PM
$MREO
0 · Reply
saad545
saad545 Jan. 23 at 4:58 AM
$MREO don’t listen to these stupid son of bitch shorts, theg want to steal your money be selling your stock. The play here with patience. This will go to 3$
1 · Reply
realDrake
realDrake Jan. 22 at 9:34 PM
$MREO im not in this shitty stock anymore dumped a couple days ago. Lost 80$ sum. Rather trade something that actually has volume and lower share structures
2 · Reply
Brighams
Brighams Jan. 22 at 9:17 PM
$MREO Went up today
1 · Reply
slaykween
slaykween Jan. 22 at 7:39 PM
$MREO should i stay or should I go...... Hmmmmm
0 · Reply
Abdujabbar90
Abdujabbar90 Jan. 22 at 5:56 PM
$SXTP $SXTP $MREO is next News fda approved
3 · Reply
ScottyDoesntKnowMeSon
ScottyDoesntKnowMeSon Jan. 22 at 5:52 PM
$MREO once all the flippers are done, .50 should hold and we should hit .7-.8
0 · Reply
Abdujabbar90
Abdujabbar90 Jan. 22 at 5:33 PM
$SXTP $MREO is next
1 · Reply
SilentJoker34
SilentJoker34 Jan. 22 at 2:26 PM
$MREO So whats your entry price your looking for? .50? .44? .40?
1 · Reply
Kabita84
Kabita84 Jan. 21 at 9:51 PM
$MREO i made close to 90k with this..very good company..but be caution when ever buy..dont loose hope..
1 · Reply
gp422
gp422 Jan. 21 at 8:51 PM
$MREO clear signs on the 30min, nothing to worry
1 · Reply
Brighams
Brighams Jan. 21 at 6:19 PM
$MREO Some real problems here
0 · Reply
Svetli_stock
Svetli_stock Jan. 21 at 6:10 PM
$MREO From tomorrow onwards it's the trend
1 · Reply
realDrake
realDrake Jan. 21 at 5:27 PM
$MREO do you know how corny you sound.. may the best Goy win😂
2 · Reply
actiontime77
actiontime77 Jan. 21 at 4:51 PM
$MREO oversold on daily Gap filled it's just the battle between bulls and bears now may the best team win
0 · Reply
actiontime77
actiontime77 Jan. 21 at 4:40 PM
$MREO gap filled at .50
0 · Reply
LDT79
LDT79 Jan. 21 at 4:30 PM
$MREO what a fucking disaster this stock has been
1 · Reply